Seroptix
has created a powerful disease analysis system called Spectra-Molecular
Informatics, or SMI, that combines spectroscopy,
biochemistry, and informatics, to analyze differences in fluorescence
spectra and molecular profiles between diseased and normal samples.
The Company exploits these disease-specific fluorescence differences
to identify new molecular targets for pharmaceutical drug-discovery
efforts and diagnostic assay development.
SerOptix's
SMI strategy systematically acquires and
analyzes disease-specific natural fluorescence signals (intrinsic
fluorescence) and fluorescent molecular profiles employing advanced
optical, separations and computational technology. To maximize
the efficiency of the data acquisition and to establish databases
that cannot be obtained with existing commercial equipment, the
company has developed proprietary INFLIT
(Intrinsic Fluorescence Information Technology) instrumentation,
which produces high quality spectral information in extracted
samples and during analysis by molecular separation methods. Applying
these and complementary technologies, the SMI
system offers a rapid and efficient strategy to identify new disease-related
molecular targets for diagnostic product development and therapeutic
drug discovery efforts.
Based
on the physical properties surveyed by the Seroptix approach,
SMI is directed to an entirely different
set of disease-related molecular targets than will be identified
by genomic or proteomic methods, thus offering a novel and valuable
complementary target-identification strategy. The company is now
poised to aggressively expand the application of this technology
to multiple diseases where new molecular targets are especially
needed, and is establishing parallel corporate-sponsored and proprietary
programs to maximize the productivity of this system.
The
identification of a disease-specific spectral signal or molecular
target represents valuable intellectual property that the company
may sell, license or co-develop for selected applications. The
company intends to build a balanced portfolio of funded and proprietary
research efforts that support the validation of our platform technology
and sustained corporate growth through option fees, milestone
payments and royalty streams derived from products based on SerOptix
discoveries.
Seroptix
is an emerging research and development-based, biotechnology company
located in Woburn, Massachusetts. The Company is currently expanding
its capital base to enable the aggressive application of its technology,
and welcomes contact from prospective
collaborators.
